טוען...
TRO40303, a mitochondrial-targeted cytoprotective compound, provides protection in hepatitis models
TRO40303 is cytoprotective compound that was shown to reduce infarct size in preclinical models of myocardial infarction. It targets mitochondria, delays mitochondrial permeability transition pore (mPTP) opening and reduces oxidative stress in cardiomyocytes submitted to ischemia/reperfusion in vitr...
שמור ב:
| הוצא לאור ב: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492760/ https://ncbi.nlm.nih.gov/pubmed/26236486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.144 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|